Importantly, statin therapy should be more effective in treating the premature CAD associated with MOPDII than PCSK9 inhibitors since statins directly target a critical enzyme involved in the augmented SMC modulation, specifically HMGCR and cholesterol biosynthesis in SMCs. The gene discussed is HMGCR; the disease is coronary artery disorder.